# Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML

> **NCT05020665** · PHASE3 · TERMINATED · sponsor: **Kronos Bio** · enrollment: 15 (actual)

## Conditions studied

- Nucleophosmin 1-mutated Acute Myeloid Leukemia

## Interventions

- **DRUG:** Entospletinib
- **DRUG:** Placebo
- **DRUG:** Cytarabine
- **DRUG:** Anthracycline

## Key facts

- **NCT ID:** NCT05020665
- **Lead sponsor:** Kronos Bio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-11-24
- **Primary completion:** 2023-03-30
- **Final completion:** 2023-03-30
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Termination was due to significant challenges associated with study enrollment in a genetic subset of fit participants in the front-line acute myeloid leukemia (AML) setting and other challenges associated with post-COVID impacts.
- **Last updated:** 2024-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05020665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05020665, "Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05020665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*